Previous 10 | Next 10 |
home / stock / glpgf / glpgf news
Galapagos NV (GLPG) Q1 2020 Results Conference Call May 8, 2020 8:00 AM ET Company Participants Elizabeth Goodwin - Investor Relations Onno van de Stolpe - CEO Bart Filius - COO and CFO Piet Wigerinck - Chief Scientific Officer Walid Abi-Saab - Chief Medical Officer Miche...
Lately, interest for Gilead ( GILD ) stock has risen dramatically as a consequence of a potential launch of its COVID-19 drug named Remdesivir. I have been a long-term believer in this company. My investment thesis, also discussed in my December article , is based on three factors: its new ma...
MECHELEN, Belgium and KRAKOW, Poland , April 16, 2020 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) (NASDAQ: GLPG) and Ryvu Therapeutics S.A. (WSE: RVU) today announced a collaboration focused on the discovery and development of novel small molecule drugs in inflammation. ...
Source: New York Times Gilead ( GILD ) is working with regulatory authorities to provide expanded access to remdesivir, which is being offered to coronavirus patients: Gilead Sciences ((GILD)) has been working with regulatory authorities to start additional expanded access prog...
There is a lot of uncertainty in the market that the number of Coronavirus cases will keep increasing exponentially. This could cost tens of thousands of peoples' lives and would impact the worldwide economy, which was already poor . Although the real consequences are still unclear, it will c...
Galapagos Receives Rating Downgrade, Stock Skids Galapagos NV ( GLPG ) stock was hit hard as Bank of America downgraded its rating to Sell. The latest downgrade comes after a couple of other such negative recommendations made by other stock research firms. The pharma company stock was rece...
The ability of Gilead Sciences ( GILD ) to make a run at new highs must speak to bullishness surrounding the coronavirus because the biopharma is struggling to complete the expected turnaround. In addition, new management made the unwise decision to remove stock-based compensation from non...
Galapagos NV (GLPG) Q4 2019 Earnings Conference Call February 21, 2020 08:00 AM ET Company Participants Elizabeth Goodwin - Vice President, Investor Relations Onno van de Stolpe - Chief Executive Officer Bart Filius - Chief Operating Officer & Chief Financial Officer Walid ...
The following slide deck was published by Galapagos NV in conjunction with their 2019 Q4 earnings Read more ...
Source: Barron's Gilead ( GILD ) reported a Q4 revenue of $5.88 billion, Non-GAAP EPS of $1.30 and GAAP EPS of $2.12. The stock is flat post-earnings. I have been bearish on Gilead for a few years now. The company's top line has gone through fits and starts and it will likely continue th...
News, Short Squeeze, Breakout and More Instantly...
Galapagos Genomics Ord Company Name:
GLPGF Stock Symbol:
OTCMKTS Market:
Galapagos Genomics Ord Website:
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual Euro...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown enc...
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers Collaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access ...